系统性红斑狼疮患者的宫颈肿瘤风险:一项全国性研究
SLE患者发生任何宫颈肿瘤的风险显著升高(HR=2.12,95%CI 1.65-2.71),CIN1和CIN2-3风险亦升高,但浸润性宫颈癌风险未显著增加。使用其他免疫抑制剂者的风险高于使用抗疟药者。
要点
- SLE女性宫颈肿瘤总体风险为普通人群2.12倍(95%CI 1.65-2.71)。
- CIN1和CIN2-3风险升高,但浸润性宫颈癌风险未显著增加。
- 使用其他免疫抑制剂者宫颈肿瘤风险高于使用抗疟药者。
核心结论
- SLE是宫颈肿瘤的危险因素,尤其对癌前病变。
- SLE患者中,使用免疫抑制剂者风险高于使用抗疟药者。
研究设计与样本
- 定义两个治疗亚组:抗疟药组1942例,其他免疫抑制剂组(AZA、CYC、环孢素、MTX、MMF或利妥昔单抗)2175例。
- 主要结局为随访期间首次宫颈肿瘤(异型增生或癌),次要结局为首次CIN1、CIN2-3和浸润性宫颈癌(2006-12年)。
- 采用Cox回归模型估计相对风险,调整年龄、教育水平、医疗利用、子女数、婚姻状况、宫颈癌家族史和既往宫颈筛查。
主要发现
- 与普通人群相比,任何宫颈肿瘤风险升高:HR=2.12(95%CI 1.65-2.71)。
- CIN1风险升高:HR=2.33(95%CI 1.58-3.44)。
- CIN2-3风险升高:HR=1.95(95%CI 1.43-2.65)。
- 浸润性宫颈癌风险未显著增加:HR=1.64(95%CI 0.54-5.02)。
关键数值与推荐
- 任何宫颈肿瘤:HR=2.12(95%CI 1.65-2.71)。
- CIN1:HR=2.33(95%CI 1.58-3.44)。
- CIN2-3:HR=1.95(95%CI 1.43-2.65)。
- 浸润性宫颈癌:HR=1.64(95%CI 0.54-5.02)。
临床怎么用
- SLE女性应重视宫颈肿瘤筛查,尤其关注癌前病变。
- 使用其他免疫抑制剂的SLE患者宫颈肿瘤风险更高,需加强监测。
- 使用抗疟药者的宫颈肿瘤风险相对较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to examine the risk of cervical neoplasia in women with SLE, overall and with respect to treatment, compared with women from the general population. METHODS: By linking national Swedish registers, we assembled a cohort including women with SLE (n = 4976) and matched general population comparators (n = 29 703). Two subcohorts of treated SLE patients were defined on the basis of treatment with antimalarials (n = 1942) and other immunosuppressants (AZA, CYC, ciclosporin, MTX, MMF or rituximab; n = 2175). The main outcome was defined as a first cervical neoplasia (dysplasia or cancer) during follow-up. Secondary outcomes were first cervical intraepithelial neoplasia (CIN) 1; first CIN grades 2-3; and first invasive cervical cancer during follow-up (2006-12). Cox regression models estimated relative risks adjusted for age, level of education, health-care utilization, number of children, marital status, family history of cervical cancer and prior cervical screening. RESULTS: Based on 121 events of cervical neoplasia during 23 136 person-years among SLE patients, there was an increased risk of any cervical neoplasia compared with the general population [hazard ratio (HR) = 2.12 (95% CI: 1.65, 2.71)]. The risk of CIN 1 [HR = 2.33 (95% CI: 1.58, 3.44)], CIN 2-3 [HR = 1.95 (95% CI: 1.43, 2.65)], but not invasive cervical cancer [HR = 1.64 (95% CI: 0.54, 5.02)], was increased in women with SLE. The subcohort treated with other immunosuppressants was at highest risk of cervical neoplasia. CONCLUSION: SLE is a risk factor for cervical neoplasia, in particular for pre-malignant cervical lesions. Among patients with SLE, the risk is higher among those treated with immunosuppresants compared with those treated with antimalarials.
引用
- Wadström H, Arkema EV, Sjöwall C, et al. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017. PMID: 28039412. doi:10.1093/rheumatology/kew459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。